The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Molecular and cellular mechanisms of pharmacoresistance in epilepsy
Abstract
Epilepsy is a common and devastating neurological disorder. In many patients with epilepsy, seizures are well-controlled with currently available anti-epileptic drugs (AEDs), but a substantial (∼30%) proportion of patients continue to have seizures despite carefully optimized drug treatment. Two concepts have been put forward to explain the development of pharmacoresistance. The transporter hypothesis contends that the expression or function of multidrug transporters in the brain is augmented, leading to impaired access of AEDs to CNS targets. The target hypothesis holds that epilepsy-related changes in the properties of the drug targets themselves may result in reduced drug sensitivity. Recent studies have started to dissect the molecular underpinnings of both transporter- and target-mediated mechanisms of pharmacoresistance in human and experimental epilepsy. An emerging understanding of these underlying molecular and cellular mechanisms is likely to provide important impetus for the development of new pharmacological treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Epilepsy: A Comprehensive Textbook
(2008) · JAMA · doi:10.1001/jama.300.4.443-a · Cited by 2,341
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Nomenclature of Voltage-Gated Sodium Channels
Goldin, A. L., Barchi, R. L., Caldwell, J. H., Hofmann, F., Howe, J. R., Hunter, J. C., Kallen, R. G., Mandel, G., Meisler, M. H., Netter, Y. B., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)00116-1 · Cited by 1,481
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
Hyperpolarization-Activated Cation Currents: From Molecules to Physiological Function
Robinson, R. B., & Siegelbaum, S. A. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142734 · Cited by 1,177
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M. (2001) · Genome Research · doi:10.1101/gr.gr-1649r · Cited by 1,113
Cited by
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
“BBB disruption in different pathological conditions BBB dysfunction is reported in many CNS pathological conditions including multiple sclerosis [161]; hypoxic and ischemic insult [162]; Parkinson’s and Alzheimer’s disease [163]; epilepsy [164]; brain tumors [165]; glaucoma [166], and lysosomal storage diseases [167].”
BackgroundKwan, P., Schachter, S. C., & Brodie, M. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004418 · Cited by 1,052
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Tang, F., Hartz, A. M. S., & Bauer, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00301 · Cited by 482
The Blood–Brain Barrier and Epilepsy
Oby, E., & Janigro, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00817.x · Cited by 388
Linalool: a review on a key odorant molecule with valuable biological properties
Aprotosoaie, A. C., Hăncianu, M., Costache, I., & Miron, A. (2014) · Flavour and Fragrance Journal · doi:10.1002/ffj.3197 · Cited by 343
Several major antiepileptic drugs are substrates for human P-glycoprotein
Luna-Tortós, C., Fedrowitz, M., & Löscher, W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.032 · Cited by 310
The clinical impact of pharmacogenetics on the treatment of epilepsy
Löscher, W., Klotz, U., Zimprich, F., & Schmidt, D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01716.x · Cited by 281
The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674483 · Cited by 269
Neurovascular Unit: a Focus on Pericytes
Sá-Pereira, I., Brites, D., & Brito, M. A. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8244-2 · Cited by 267
Elger, C., Halász, P., Maia, J., Almeida, L., Soares‐da‐Silva, P., & on behalf of the BIA‐2093‐301 Investigators Study Group (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01946.x · Cited by 252
Dissecting axes of autonomic control in humans: insights from neuroimaging
Critchley, H. D., Nagai, Y., Gray, M. A., & Mathias, C. J. (2011) · Autonomic Neuroscience · doi:10.1016/j.autneu.2010.09.005 · Cited by 152
Bypassing the Blood–Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies
Gernert, M., & Feja, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121134 · Cited by 68
Wang, Y., Ying, X., Chen, L., Liu, Y., Wang, Y., Liang, J., Xu, C., Guo, Y., Wang, S., Hu, W., et al. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0431-9 · Cited by 65
Metadata
- Authors
- Remy, S., & Beck, H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-29
- Volume
- 129
- Issue
- 1
- Pages
- 18-35
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2126829625
- Cited by
- 406
- References
- 168
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.